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Is integrating sickle cell disease and HIV screening logical?
Sickle cell disease is the most prevalent genetic disorder 
worldwide, with burden being highest in countries with 
constrained resources and endemic malaria. With very 
poor survival in children and severe morbidity in older 
survivors, the health-care infrastructures in the worst-
aﬀ ected parts of the world are overwhelmed. Diagnosis 
is frequently made only when complications occur, 
and supportive care is commonly poor.1 In contrast, in 
several developed countries with much lower prevalence, 
neonatal screening has become the norm, and has led to 
institution of early preventive and supportive care that 
have substantially improved outcomes.
In The Lancet Global Health, Grace Ndeezi and 
colleagues2 report the Uganda Sickle Surveillance 
Study (US3), done in collaboration with Cincinnati 
Children’s Hospital Medical Center, OH, USA, which 
used a simple but innovative approach to screening 
infants (younger than 18 months) for sickle cell trait 
and disease. They used residual dried blood spots 
collected for the Early Infant Diagnosis programme for 
HIV in ten regions (112 districts) of the country and used 
isoelectric focusing analysis of haemoglobin to calculate 
prevalence. 99 243 samples were screened, with 
results available from 97 631. The overall prevalence 
of sickle cell trait ranged from 4·6% to 19·8% and for 
disease from 0·2% to 1·5%. Sickle cell disease was less 
prevalent among children older than 12 months than 
among younger children (0·6% vs 0·8% in children 
aged 0–6·0 months and 0·7% in children aged older 
than 6·0 to 12·0 months) and in those with comorbid 
HIV than in those negative for HIV (0·5% vs 0·8%). The 
national prevalence of haemoglobin variants was 0·5% 
(range across regions 0·1–1·8). 
Although high and variable frequencies of sickle cell 
trait in diﬀ erent ethnic groups in Uganda have been 
reported previously,3 those data were from around 
70 years ago and were based on small sample sizes. 
Thus, the ﬁ ndings of Ndeezi and colleagues provide a 
contemporary overview that is nationally representative. 
While the genesis of the S mutation is well recognised 
as a secondary factor to the endemicity of malaria and 
natural selection, the time is ripe to begin to address the 
genesis of new variants and their importance.
The children assessed in US3 were enrolled in the Early 
Infant Diagnosis programme for HIV screening and did 
not provide consent to be tested for sickle cell disease, 
a genetic disorder. Furthermore, the results were 
communicated to the families but optimum clinical care 
could not be assured. The ethical justiﬁ cation for this 
study could be debated, as it is unlikely that it would 
have been permissible in most developed countries, 
where the use of residual neonatal dried blood spots for 
research purposes has been challenged.4 Nevertheless, 
the Ugandan Government and Ministry of Health 
deserve commendation for making an important 
decision in favour of public health. This study provides 
an excellent example of a meaningful integration of 
screening programmes to provide useful data for health 
planning that could be emulated by other countries in 
sub-Saharan Africa, where sickle cell is highly prevalent 
and early infant diagnosis programmes are in place. 
Much too often in these countries, ministries of health 
partner with foreign donors to run several parallel 
programmes that are expensive and sometimes 
counterproductive. 
23 (0·5%) of 5080 children with HIV assessed by Ndeezi 
and colleagues also had sickle cell disease, compared 
with 693 (0·8%) of 92 024 who were HIV negative. 
This ﬁ nding suggests early mortality in children with 
comorbid sickle cell disease and HIV, and should be 
studied further. Several case reports suggest that sickle 
cell disease slows the progression of HIV,5,6 for which 
several hypotheses have been proposed that might oﬀ er 
new leads for HIV treatments.5–7 Almost all these reports, 
however, involved patients with horizontal infection. 
What happens in infants who acquire infection vertically 
and have sickle cell disease remains unclear and warrants 
exploration, for which there cannot be a better natural 
platform than where both disorders are highly prevalent. 
The introduction of early diagnosis of sickle cell disease 
in African countries would provide a unique opportunity 
to assess the interaction between this disorder and HIV.
The time for a worldwide concerted eﬀ ort to control 
sickle cell disease is long overdue. Although technical 
support can be provided by partners in developed 
countries, as was the case in US3,2 the ultimate and long-
term care of patients remains the prerogative of the 
host country. African countries and leaders, therefore, 
must own up to this responsibility, improve funding 
allocation for supporting care, and use appropriate 
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media to promote public awareness and strategies to 
reduce incidence.
Finally, the goal of preventing early death in people 
with sickle cell disease in sub-Saharan Africa goes well 
beyond neonatal screening. In Brazil, such screening has 
not been associated with a substantial decline in early 
mortality.8 Thus, while early diagnosis is logical, what 
is more important is to provide good care afterwards, 
otherwise a neonatal screening programme could easily 
become another way of increasing the existing pool of 
people known to be aﬀ ected by sickle cell disease. 
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